(MedPage Today) — The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase II studies, but two treatments — pridopidine and CNM-Au8 — showed glimmers of hope.
All treatments…
Source link : https://www.medpagetoday.com/neurology/generalneurology/114246
Author :
Publish date : 2025-02-17 16:01:00
Copyright for syndicated content belongs to the linked Source.
